[go: up one dir, main page]

MXPA02004441A - Derivados de isoxazol como inhibidores de la fosfodiesterasa. - Google Patents

Derivados de isoxazol como inhibidores de la fosfodiesterasa.

Info

Publication number
MXPA02004441A
MXPA02004441A MXPA02004441A MXPA02004441A MXPA02004441A MX PA02004441 A MXPA02004441 A MX PA02004441A MX PA02004441 A MXPA02004441 A MX PA02004441A MX PA02004441 A MXPA02004441 A MX PA02004441A MX PA02004441 A MXPA02004441 A MX PA02004441A
Authority
MX
Mexico
Prior art keywords
phosphodiesterase vii
isoxazole derivatives
vii inhibitors
inhibitors
phosphodiesterase
Prior art date
Application number
MXPA02004441A
Other languages
English (en)
Inventor
Welge Thomas
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA02004441A publication Critical patent/MXPA02004441A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente invencion se refiere a compuestos de la formula 1 (ver formula) donde R1, R2, R3, R4 y R5 tienen los significados indicados en la reivindicacion 1, y sus sales y solvatos fisiologicamente inofensivos, como inhibidor de la fosfodiesterasa VII y su utilizacion para fabricar un medicamento.
MXPA02004441A 1999-11-04 2002-05-03 Derivados de isoxazol como inhibidores de la fosfodiesterasa. MXPA02004441A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19953024A DE19953024A1 (de) 1999-11-04 1999-11-04 Isoxazolderivate als Phosphodiesterase VII-Hemmer

Publications (1)

Publication Number Publication Date
MXPA02004441A true MXPA02004441A (es) 2004-09-10

Family

ID=7927860

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02004441A MXPA02004441A (es) 1999-11-04 2002-05-03 Derivados de isoxazol como inhibidores de la fosfodiesterasa.

Country Status (20)

Country Link
US (1) US6531498B1 (es)
EP (1) EP1225896B1 (es)
JP (1) JP2003513042A (es)
KR (1) KR20020047329A (es)
CN (1) CN1384744A (es)
AR (1) AR026350A1 (es)
AT (1) ATE300945T1 (es)
AU (1) AU781607B2 (es)
BR (1) BR0015333A (es)
CA (1) CA2389647C (es)
CZ (1) CZ20021441A3 (es)
DE (2) DE19953024A1 (es)
ES (1) ES2243313T3 (es)
HU (1) HUP0203187A3 (es)
MX (1) MXPA02004441A (es)
NO (1) NO20022123L (es)
PL (1) PL355021A1 (es)
RU (1) RU2002113746A (es)
SK (1) SK5942002A3 (es)
WO (1) WO2001032175A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522425A (ja) * 1998-08-07 2002-07-23 カイロン コーポレイション エストロゲンレセプターモジュレーターとしての置換イソオキサゾール
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
KR100666052B1 (ko) * 2004-02-12 2007-01-09 조극래 원적외선이용한 건조장치
ES2814200T3 (es) * 2005-07-29 2021-03-26 Basf Se Estabilización de productos para el cuidado del cuerpo y del hogar contra la degradación por radiación UV utilizando derivados de merocianina
MX2009010450A (es) * 2007-03-27 2009-11-23 Omeros Corp El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
JP2014504271A (ja) 2010-11-08 2014-02-20 オメロス コーポレーション Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN104725329B (zh) * 2015-01-13 2017-01-18 陕西科技大学 一种具有抗肿瘤活性的异恶唑羧酸类化合物及其合成方法
AU2018300091B2 (en) 2017-07-12 2023-06-22 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
CN119894518A (zh) 2022-08-18 2025-04-25 米托迪治愈有限责任公司 取代的苯并噁唑和苯并呋喃化合物用于治疗和预防与慢性疲劳、筋疲力尽和/或劳累不耐受相关的疾病的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658629B2 (en) * 1991-05-01 1995-04-27 Taiho Pharmaceutical Co., Ltd. Novel isoxazole derivative and salt thereof
PT730587E (pt) 1993-11-26 2000-05-31 Pfizer 3-aril-2-isoxazolinas como agentes anti-inflamatorios
ES2104424T3 (es) * 1993-11-26 1997-10-01 Pfizer Compuestos de isoxazolina como agentes antiinflamatorios.

Also Published As

Publication number Publication date
AU1026201A (en) 2001-05-14
KR20020047329A (ko) 2002-06-21
DE19953024A1 (de) 2001-05-10
ATE300945T1 (de) 2005-08-15
NO20022123D0 (no) 2002-05-03
ES2243313T3 (es) 2005-12-01
PL355021A1 (en) 2004-03-22
EP1225896B1 (de) 2005-08-03
US6531498B1 (en) 2003-03-11
BR0015333A (pt) 2002-07-09
HUP0203187A2 (hu) 2003-01-28
NO20022123L (no) 2002-05-03
RU2002113746A (ru) 2004-01-10
EP1225896A1 (de) 2002-07-31
SK5942002A3 (en) 2002-09-10
AU781607B2 (en) 2005-06-02
JP2003513042A (ja) 2003-04-08
CZ20021441A3 (cs) 2002-07-17
CA2389647A1 (en) 2001-05-10
DE50010885D1 (de) 2005-09-08
HUP0203187A3 (en) 2004-12-28
CN1384744A (zh) 2002-12-11
WO2001032175A1 (de) 2001-05-10
AR026350A1 (es) 2003-02-05
CA2389647C (en) 2010-08-10

Similar Documents

Publication Publication Date Title
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
SE0202463D0 (sv) Novel compounds
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
HRP20031003A2 (en) 4'-substituted nukleosides
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
ATE316083T1 (de) Adamantanderivate
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
BG103195A (en) Substituted indazole derivatives and their application as inhibitors of phosphodiesterase (pde) type iv and of the production of a tumournecrotic factor (tnf)
YU69902A (sh) Novi derivati piperazina
MY133392A (en) Novel substituted pyrazole derivatives
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
AU2003269327A1 (en) Tetrahydroquinoline derivatives as crth2 antagonists
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
CA2499330A1 (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2004100865A3 (en) New benzimidazole derivatives
SE9701304D0 (sv) Compounds
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
GB0109122D0 (en) Novel compounds
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
WO2003066594A3 (de) 3-alkanoylamino-propionsäure-derivate als inhibitoren des integrins avss6
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors